HILLSIDE, N.J., July 10 /PRNewswire-FirstCall/ -- INB:Biotechnologies Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. announces commencement of dosing of PhytoSel(R) in a Phase I clinical trial. The study, conducted at City of Hope in Duarte, Calif., will examine whether high doses of Phytosel(R), INB's proprietary plant-derived oral formulation of selenium, can reduce the negative side effects of two chemotherapeutic drugs. The trial is expected to take approximately one year to complete.
PhytoSel(R) has been marketed within the nutraceutical industry for several years as a natural selenium supplement. The micronutrient consists of organic selenium compounds that are produced using INB's patented hyperaccumulation process.
This Phase I trial is being conducted at City of Hope where the initial dosing is underway. Stephen Shibata, M.D., principal investigator for the study, is a physician in the Department of Medical Oncology & Therapeutics Research at City of Hope.
About City of Hope
City of Hope is one of the world's leading research and treatment centers for cancer, diabetes, HIV/AIDS and other life-threatening diseases. Named by U.S.News & World Report as one of America's best medical centers for cancer treatment, City of Hope is a Comprehensive Cancer Center, the highest designation bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. City of Hope's scientific knowledge is shared with medical centers locally and globally, helping patients battling life-threatening diseases. For more information, visit www.cityofhope.org.
About Integrated BioPharma Inc (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Integrated BioPharma, Inc.CONTACT: Dina Masi, CFO, Integrated BioPharma, Inc, +1-888-319-6962, ord.masi@ibiopharma.com
